Mattias Neyt1, Thierry Christiaens2,3, Jacques Demotes4, Tom Walley5,6, Frank Hulstaert1. 1. Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium. 2. Ghent University, Belgium. 3. Belgian Centre for Pharmacotherapeutic Information (BCFI), Belguim. 4. European Clinical Research Infrastructure Network (ECRIN), Paris, France. 5. University of Liverpool, UK. 6. National Institute for Health Research (NIHR), UK.
Abstract
AIM: Many questions of relevance to patients/society are not answered by industry-sponsored clinical trials. We consider whether there are benefits to governments in funding practice-oriented clinical trials. METHODOLOGY: A literature search including publications on institutions' websites was performed and supplemented with information gathered from (inter)national stakeholders. RESULTS: Areas were identified where public funding of clinical trials is of importance for society, such as head-to-head comparisons or medical areas where companies have no motivation to invest. The available literature suggests publicly funded research programs could provide a positive return on investment. The main hurdles (e.g., sufficient funding and absence of equipoise) and success factors (e.g., selection of research questions and research infrastructure) for the successful conduct of publicly funded trials were identified. CONCLUSION: Governments should see public funding of pragmatic practice-oriented clinical trials as a good opportunity to improve the selection and quality of treatments and stimulate efficient use of limited resources.
AIM: Many questions of relevance to patients/society are not answered by industry-sponsored clinical trials. We consider whether there are benefits to governments in funding practice-oriented clinical trials. METHODOLOGY: A literature search including publications on institutions' websites was performed and supplemented with information gathered from (inter)national stakeholders. RESULTS: Areas were identified where public funding of clinical trials is of importance for society, such as head-to-head comparisons or medical areas where companies have no motivation to invest. The available literature suggests publicly funded research programs could provide a positive return on investment. The main hurdles (e.g., sufficient funding and absence of equipoise) and success factors (e.g., selection of research questions and research infrastructure) for the successful conduct of publicly funded trials were identified. CONCLUSION: Governments should see public funding of pragmatic practice-oriented clinical trials as a good opportunity to improve the selection and quality of treatments and stimulate efficient use of limited resources.
Authors: C Madeira; L Hořavová; F Dos Santos; J R Batuca; K Nebeska; L Součková; C Kubiak; J Demotes; R Demlová; E C Monteiro Journal: Ther Innov Regul Sci Date: 2021-05-18 Impact factor: 1.778
Authors: Snezana Djurisic; Ana Rath; Sabrina Gaber; Silvio Garattini; Vittorio Bertele; Sandra-Nadia Ngwabyt; Virginie Hivert; Edmund A M Neugebauer; Martine Laville; Michael Hiesmayr; Jacques Demotes-Mainard; Christine Kubiak; Janus C Jakobsen; Christian Gluud Journal: Trials Date: 2017-08-01 Impact factor: 2.279